Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40).
Open Access
- 1 February 1987
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 138 (3) , 788-794
- https://doi.org/10.4049/jimmunol.138.3.788
Abstract
We recently described a 50,000 dalton polypeptide Bp50 (CDw40) that is expressed on human B cells and plays a role in regulating B cell proliferation. Here we additionally characterize the functional signal given by antibody binding to Bp50 on both normal and malignant B cells. A monoclonal anti-Bp50 antibody could augment the proliferation of B cells activated by anti-IgM, anti-CD20, or 12-O-tetradecanoyl phorbol-13-acetate (TPA) stimulation, but was not co-stimulatory with B cell growth factor (BCGF), interleukin 1, or interleukin 2. The signal did not depend on the Fc portion of the antibody, because F(ab')2 fragments of anti-Bp50 were still functionally active. Both anti-Bp50 and a low m.w. BCGF preparation were similar in that both were co-stimulatory with the same agents and both anti-Bp50 and BCGF affected activated B cells but not resting B cells. However, a panel of B cell malignancies differed in their responsiveness to anti-Bp50 vs BCGF: some tumors proliferated in response to anti-Bp50 but not BCGF, whereas other tumors had the opposite pattern. Bp50 was found to have several properties in common with HLA class II molecules: both Bp50 and class II were expressed at lower levels on blood B cells than on tonsillar B cells; the expression of both Bp50 and class II was increased after activation of blood B cells with TPA or anti-IgM; and the expression of both Bp50 and class II was increased after activation of non T, non-B acute leukemias with BCGF. Thus class II and Bp50 expression may be under common regulatory control. The fact that BCGF modulated the expression of Bp50 on leukemic cells suggests that BCGF and Bp50-mediated signals may be coordinately regulated.This publication has 10 references indexed in Scilit:
- Purification to homogeneity of a high molecular weight human B cell growth factor; demonstration of specific binding to activated B cells; and development of a monoclonal antibody to the factor.The Journal of Experimental Medicine, 1985
- Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression.The Journal of Immunology, 1985
- Human B cell responsiveness to B cell growth factor after activation by phorbol ester and monoclonal anti-mu antibody.The Journal of Immunology, 1985
- Human B lymphoma cell line producing B cell growth factor.Journal of Clinical Investigation, 1985
- Antibodies to surface IgM and IgD increase the expression of various class II antigens on human B cellsEuropean Journal of Immunology, 1985
- Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function.The Journal of Experimental Medicine, 1985
- Evidence for two distinct classes of murine B cell growth factors with activities in different functional assays.The Journal of Experimental Medicine, 1983
- Identification and functional characterization of two distinct epitopes on the human T cell surface protein Tp50.The Journal of Immunology, 1983
- B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation.The Journal of Experimental Medicine, 1983
- Development of a human T-T cell hybridoma secreting B cell growth factor.The Journal of Experimental Medicine, 1983